Bladder cancer trials in France

In France 70 Also abroad 626

70 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Besancon Cedex, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain, Strasbourg Cedex 2, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Where
Bordeaux, Dijon, Paris, Rouen Cedex, Suresnes
Age
18 years and over
People
308 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06833073 · EU 2024-517335-46-00
Phase 2Not yet taking people in France
Hex-SUB1-IPC 2025-067 - PROOF OF CONCEPT: FEASIBILITY OF PHOTODYNAMIC DIAGNOSIS IN BLADDER CANCER PATIENTS WITH SUB-ONE-HOUR INSTILLATION TIME OF HEXAMINOLEVULINATE (HEXVIX®)
Where
Marseille
Age
18 years and over
People
50
Run by
Institut Paoli Calmettes
See details and how to join2026-526917-27-00 · EU 2026-526917-27-00
Phase 3Taking people
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma.
Where
Bordeaux, Montpellier Cedex 5, Paris, Pierre-Bénite, Poitiers, Strasbourg Cedex 2
Age
18 years to 64 years
People
262 worldwide
Run by
AstraZeneca AB
See details and how to join2025-525030-57-00 · EU 2025-525030-57-00
Phase 2Taking people
A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder.
Where
Angers, Bordeaux, Clermont-Ferrand, Grenoble Cedex 9, Lille Cedex, Lyon, Marseille, Paris, Rennes Cedex, Strasbourg, Strasbourg Cedex 2, Suresnes, Toulouse, Villejuif
Age
18 years and over
People
88 worldwide
Run by
Astellas Pharma Global Development Inc.
See details and how to join2025-524488-18-00 · EU 2025-524488-18-00
No phaseTaking people
Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis
Where
Clermont-Ferrand
Age
18 years and over
People
150
Run by
University Hospital, Clermont-Ferrand
See details and how to joinNCT05464576
Phase 1/2Taking people
Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis
Where
Paris
Age
18 years and over
People
20 worldwide
Run by
Ferring Pharmaceuticals
See details and how to joinNCT06668493 · EU 2024-514360-70-00
No phaseTaking people
Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)
Where
Strasbourg
Age
18 years and over
People
100
Run by
University Hospital, Strasbourg, France
See details and how to joinNCT07820566
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Besançon, Levallois-Perret, Marseille, Neuilly, Paris
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 1Taking people
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Where
Dijon, Saint-Herblain, Toulouse
Age
18 years and over
People
383 worldwide
Run by
Iambic Therapeutics, Inc
See details and how to joinNCT06253871
Phase 3Taking people
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab
Where
Besancon Cedex, Bordeaux, Brest, Dijon, Lyon, Marseille, Montpellier Cedex 5, Rennes Cedex, Rouen Cedex, St Herblain, Strasbourg, Toulouse Cedex 9, Tours Cedex 9, Villejuif
Age
18 years and over
People
87 worldwide
Run by
Astrazeneca AB
See details and how to joinNCT05303532 · EU 2023-507337-22-00
Phase 1Taking people
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Where
Lyon
Age
18 years and over
People
150 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644755
No phaseTaking people
Relevance of the Urine Bacterial Culture Performed Before TransUrethral Resection of the Bladder for Post-operative Febrile Urinary Tract Infections Prevention: a Non-inferiority Randomized Controlled Trial
Where
Angers, Grenoble, Le Coudray, Lille, Lyon, Marseille, Mont-de-Marsan, Nantes, Paris, Poitiers, Quint-Fonsegrives, Talence, Tours, Vandœuvre-lès-Nancy
Age
18 years and over
People
2,600
Run by
Poitiers University Hospital
See details and how to joinNCT07463963
Phase 2/3Taking people
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Where
Angers, Bordeaux, Brest, Calais, Cedex 10, Créteil, Grenoble, La Chaussée-Saint-Victor, La Roche-sur-Yon, Le Mans, Lyon, Marseille, Montpellier, Nantes, Nîmes, Paris, Pierre-Bénite, Poitiers, Quint-Fonsegrives, Reims, Saint-Etienne, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy
Age
18 years and over
People
630 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT07129993
Phase 1/2Taking people
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Where
Bordeaux, Lille, Lyon, Nantes, Strasbourg, Strasbourg Cedex 2, Villejuif
Age
18 years and over
People
300 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00
Phase 1/2Taking people
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Where
Villejuif
Age
18 years and over
People
366 worldwide
Run by
Marengo Therapeutics, Inc.
See details and how to joinNCT05592626 · EU 2023-505334-10-01
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Clermont Ferrand Cedex1, Dijon, La Tronche, Lyon, Marseille, Nantes, Pessac, Toulouse Cedex 9, Vandoeuvre Les Nancy
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
Phase 1/2Taking people
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Where
Angers, Bordeaux, Lille Cedex, Lyon Cedex 03, Paris Cedex 18, Rouen Cedex
Age
18 years and over
People
350 worldwide
Run by
enGene, Inc.
See details and how to joinNCT04752722 · EU 2024-512900-20-00
Phase 1Not yet taking people in France
A First In Human Phase I Trial Evaluating safety, tolErability and ResponSe of [211At]At-Girentuximab (ATO-101™) in PatiEnts with Non-Muscle-InVasive BladdER CANCEr Refractory to Standard Treatment (PERSEVERANCE EU)
Where
Saint-Herblain Cedex
Age
18 years and over
People
24
Run by
Institut De Cancerologie De L Ouest
See details and how to join2023-509729-33-00 · EU 2023-509729-33-00
Phase 2/3Taking people
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Where
Bordeaux, Brest, Clermont-Ferrand, Lyon Cedex08, Marseille, Nice, Paris, Saint-Herblain, Strasbourg, Suresnes, Villejuif
Age
18 years and over
People
470 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07106762
Phase 2Taking people
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Where
Angers, Bordeaux, Brest, Marseille, Paris Cedex 13, Toulouse Cedex 9, Villejuif
Age
8 years and over
People
254 worldwide
Run by
Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00
Phase 2Taking people
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Where
Lyon, Nice Cedex 2, Paris, Strasbourg, Villejuif
Age
18 years and over
People
372 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04879329 · EU 2022-500030-28-01
Phase 3Taking people
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Where
Bordeaux, Montpellier, Paris, Pierre-Bénite, Poitiers, Strasbourg
Age
18 years and over
People
915 worldwide
Run by
AstraZeneca
See details and how to joinNCT07720284
Phase 1Taking people
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Where
Angers, Nice Cedex 2, Poitiers, Vandouvre Les Nancy, Villejuif
Age
18 years and over
People
1,006 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT04389632 · EU 2023-508469-34-00
Phase 1/2Taking people
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Where
Dijon, Marseille, Toulouse, Villejuif
Age
18 years and over
People
180 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00